Castle Biosciences Balance Sheet
NASDAQ: CSTLHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Castle Biosciences financial position
At the end of fiscal 2025, Castle Biosciences reported total assets of $578.6 million, up 8.9% from a year earlier against total liabilities of $107.7 million. Shareholders' equity stood at $470.9 million, or 81.4% of assets. The company held $116.7 million in cash and equivalents against $10.1 million of debt, a net cash position of $106.7 million.
The current ratio (current assets divided by current liabilities) was 5.26, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.02.
Summary generated from market data by MetaCap's automated system. Methodology
Castle Biosciences balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 116.73M | 119.71M | 98.84M | 122.95M | 329.63M | 409.85M | 98.84M | 4.48M |
| Short-Term Investments | 182.78M | 173.42M | 144.26M | 135.68M | 0 | — | — | — |
| Receivables | 43.38M | 51.22M | 38.30M | 23.48M | 17.28M | 12.76M | 14.65M | 12.09M |
| Inventory | 10.25M | 8.13M | 7.94M | 3.98M | 2.02M | 2.22M | 1.24M | 882.00K |
| Total Current Assets | 361.10M | 360.15M | 295.63M | 292.29M | 353.74M | 429.59M | 116.68M | 18.13M |
| Property, Plant & Equipment | 97.44M | 51.12M | 25.43M | 14.31M | 9.50M | 7.10M | 2.06M | 1.53M |
| Goodwill | 10.70M | 10.70M | 10.70M | 10.70M | 0 | — | — | — |
| Intangible Assets | 88.88M | 95.54M | 106.64M | 115.66M | 88.92M | 0 | 0 | 4.00K |
| Long-Term Investments | — | 0 | — | — | — | — | — | — |
| Total Assets | 578.56M | 531.24M | 453.34M | 447.33M | 462.57M | 439.33M | 119.75M | 22.41M |
| Accounts Payable | 18.71M | 6.90M | 10.27M | 4.73M | 2.55M | 2.10M | 1.86M | 1.45M |
| Short-Term Debt | 417.00K | 278.00K | 0 | — | — | 0 | 5.83M | 0 |
| Total Current Liabilities | 68.68M | 49.39M | 47.67M | 36.13M | 24.89M | 20.88M | 15.29M | 6.74M |
| Long-Term Debt | 9.64M | 9.74M | 0 | — | — | 0 | 19.29M | 24.50M |
| Total Liabilities | 107.68M | 75.40M | 62.07M | 48.18M | 50.83M | 23.64M | 34.63M | 32.48M |
| Shareholders' Equity | 470.87M | 455.83M | 391.27M | 399.15M | 411.74M | 415.69M | 85.11M | -56.57M |
| Retained Earnings | -224.28M | -200.13M | -218.37M | -160.91M | -93.77M | -62.50M | -52.21M | -57.49M |
| Total Debt | 10.06M | 10.02M | 0 | — | — | 0 | 25.12M | 24.50M |
| Net Cash (Debt) | 289.45M | 283.11M | 243.10M | 258.63M | 329.63M | 409.85M | 73.72M | -20.02M |
| Shares Outstanding | 29.69M | 28.48M | 27.41M | 26.55M | 25.38M | 24.81M | 17.13M | 1.92M |
This table shows 8 annual periods of Castle Biosciences's balance sheet, from FY 2025 back to FY 2018, across 20 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CSTL's reporting calendar. What is a balance sheet?